-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Swiss biotech company ADC Therapeutics SA recently announced new data from two clinical trials of CD19 targeted antibody conjugate (ADC) Zynlonta (loncastuximab tesirine-lpyl) at the 16th International Annual Conference on Malignant Lymphoma (ICML)
The latest results from the LOTIS-2 trial demonstrate Zynlonta’s long-lasting response in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have been heavily-preteated (previously received multiple therapies) The median duration of response (DOR) reached 13.
Zynlonta is an antibody-conjugated drug (ADC) targeting CD19.
Molecular structure of loncastuximab tesirine
In April 2021, Zynlonta received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) who have received 2 or more systemic therapies, including diffuse Large B-cell lymphoma (DLBCL), DLBCL originating from low-grade lymphoma and high-grade cell lymphoma
In China, Zynlonta is being developed by Overland ADCT BioPharma, a joint venture established by ADC Therapeutics and Overland Pharmaceuticals
It is worth mentioning that Zynlonta is the first and only CD19-targeted ADC as a single agent to treat adult patients with r/r DLBCL
Zynlonta mechanism of action
LOTIS-2 trial follow-up analysis data:
LOTIS-2 is a single-arm, open-label clinical trial (n=145), carried out in patients with relapsed or refractory DLBCL who have previously received at least 2 systemic therapies and failed to evaluate the efficacy and efficacy of Zynlonta monotherapy.
The latest results released this time show that Zynlonta monotherapy shows sustained anti-tumor activity and acceptable safety
LOTIS-3 trial follow-up analysis data:
LOTIS-3 trial follow-up analysis data:LOTIS-3 is a phase 1/2, two-part, open-label, one-arm clinical trial that is evaluating the efficacy of Zynlonta combined with ibrutinib (ibrutinib, BTK inhibitor) in the treatment of relapsed or refractory DLBCL or MCL
Key data include: ORR of 62.
Original source: ADC Therapeutics Presents Updated ZYNLONTA (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
This article is from Bio Valley, for more information, please download the Bio Valley APP (http://